Results of laboratory tests, which were released on 20 January 2021, have indicated that the COVID-19 vaccine developed by US pharmaceutical company Pfizer Inc and its German partner BioNTech is likely to protect against a more infectious variant of the virus, which was discovered in the UK and has spread around the world, Reuters news agency reported on Wednesday.
These results, based on an analysis of blood of participants in trials, are based on more extensive analysis than those released by Pfizer last week.
Reportedly, Pfizer said last week that a similar laboratory study showed that its COVID-19 vaccine was effective against one key mutation, called N501Y, found in both of the highly transmissible new variants spreading in the UK and South Africa.
This latest study, which has not yet been peer reviewed, was conducted on 10 mutations, which are characteristic of the variant known as B117 identified in the UK, Reuters added.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial